Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OncoLAR (octreotide pamoate)
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Peptides
- Administration
- Intramuscular
01
Overview
Octreotide pamoate is a synthetic long-acting octapeptide analogue of endogenous somatostatin. It binds to somatostatin receptors expressed by some neuroendocrine and other tumor cells, inhibiting the secretion of several hormones and growth factors. The drug is formulated for extended-release (long-acting release) administration and is primarily used in the management of certain neuroendocrine tumors and related conditions[1][2].
- Brand names
- OncoLAR
- Other names
- octreotide pamoatelong-acting release octreotideLAR-octreotide
02
Targets
SSTR2 (Somatostatin receptor type 2)SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on OncoLAR (octreotide pamoate).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoLAR (octreotide pamoate).